First you’ll need to log back into 23andMe, if you can remember your details that is. Then you can submit the deletion request online, the company will email you to confirm and once you have verified ...

Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...

10月13日， 康方生物 宣布完成新一轮股票配售，成功融资约19.42亿港元。本次融资金额的70%将用于加速 康方生物 自主研发新药在全球范围内的临床开发。 诺和诺德 以其 减肥药 Wegovy闻名于世，正在利用 AI 创新来简化运营并提高效率。 通过在印度（全球最大的糖尿病药物市场之一）进行战略定位， 诺和诺德 预计将通过提高生产能力来满足日益增长的需求。

GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

Artificial intelligence chatbots cannot be relied on to give accurate, safe or even clear advice about medication, according ...

GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...

Investment in the UK will be on the agenda, with speakers from the NHS, Google and numerous insurance companies ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...